信达生物炸场

药渡
Jul 13, 2025

近期,信达生物迎来“双喜临门”:减重新药玛仕度肽注射液获批上市、完成配股融资5.5亿美元(折合人民币约40亿元)。一个是潜在大药终于来了,“2027年实现营收达到200亿元”的信心更足了;一个是剑指全球化、“成长为国际一流的生物制药企业”的野心藏不住了。上述种种信息表明,信达生物越来越强大了。01潜在大药亮相6月27日,信达生物在市场空间广阔的慢性代谢疾病领域打出了一记重拳:玛仕度肽注射液(商品名...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10